Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Court rejects FDA pre-emption claims

Executive Summary

In a June 22 ruling in a case involving Wyeth's Prempro (estrogen/progestin), New Jersey Superior Court rules that FDA approval of a drug's label is insufficient to pre-empt a product liability suit claiming inadequate warning of the product's risks. The Third Circuit U.S. Court of Appeals is set to be the first appellate court to address preemption with two pending cases (1"The Pink Sheet" April 9, 2007, p. 24)...

You may also be interested in...



FDA Preemption Policy Gets First Appeals Court Test With Zoloft, Paxil Cases

A federal appellate court will take up the issue of whether FDA approved labeling preempts state litigation claiming companies failed to warn of a product's risks, following years of conflicting rulings from district courts

Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space

Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.

Merck & Co. Files First IRA Suit, Signaling Industry Is Ready To Fight

Coming less than three months before the statutory deadline for CMS to publish the initial list of drugs, Merck’s lawsuit calls US Medicare drug price negotiations ‘extortion’ in a complaint that could be the first of more legal pushback to follow.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel